Meyonex Pharmaceuticals Limited

Meyonex Pharmaceuticals Limited - pharma in Palghar, Maharashtra, India. FY 2026 financials & compliance.
CIN U74120MH2015PLC261024 Incorporated 17 January 2015 ROC Mumbai HQ Palghar, Maharashtra, India
Active Public Limited Company pharma MSME · Medium
Data last updated
Revenue · FY 2025
₹108.15 Cr
▼ 19% YoY
Net profit · FY 2025
₹3.62 Cr
Net margin 3.3%
EBITDA · FY 2025
₹10.86 Cr
EBITDA margin 10%
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹14 Cr
Issued & subscribed
Open charges
₹21.02 Cr
Satisfied ₹25 Lakh
Company age
11 yrs
Est. 2015
Employees · EPFO
48
Provident fund records

About Meyonex Pharmaceuticals Limited

Data last updated:

Meyonex Pharmaceuticals Limited is a public limited company based in Palghar, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 January 2015 and has been in existence for over 11 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74120MH2015PLC261024. Its GSTIN is 27AANCA2009B1Z6 (Maharashtra).

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14 Cr. It was formerly known as Aveo Pharmaceuticals Limited. It is led by directors including Arvind Awadhnath Sharma and Vinod Kumar Sharma.

Its last annual general meeting (AGM) was held on 28 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot No C – 13 MIDC Tarapur Palghar, Maharashtra, India – 401506.

As per the financials filed for FY 2025, the company reported a revenue of ₹108.15 Cr, a decline of 19% compared to the previous year. For the same year it recorded a net profit of ₹3.62 Cr (net margin 3.3%) and EBITDA of ₹10.86 Cr (EBITDA margin 10%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 37% over five years.

The company has about 48 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Aveo Pharmaceutical. As per MCA filings, the company has open charges of ₹21.02 Cr and satisfied charges of ₹25 Lakh on record. Court records list 12 cases involving the company, including 9 filed by the company and 3 filed against it; 7 cases are pending. The company has 4 deals on record (2 rights issues, 1 convertible or debt financing, 1 secondary share transfer), with disclosed funding of ₹1.24 Cr; the latest was in August 2021. Its 4 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading) are compared by revenue, 2 larger and 2 smaller; the largest is Viplus Pharmaceuticals Private Limited with revenue of ₹109.48 Cr. The company has 3 MSME Form 1 returns on record between 2021 and 2022, listing 21 overdue payments to 12 micro and small suppliers.

Meyonex Pharmaceuticals Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-17-0012359). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aveo.in.

Company details

CIN U74120MH2015PLC261024
Registration Number 261024
Incorporation Date 17 January 2015
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 28 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-17-0012359

CIN history

Meyonex Pharmaceuticals has one previous CIN (Corporate Identification Number): U74120MH2015PTC261024. The current CIN is U74120MH2015PLC261024, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U74120MH2015PLC261024Current
U74120MH2015PTC261024Previous
Key People
Arvind Awadhnath Sharma Director Vinod Kumar Sharma Director Shivani Sharma Additional Director

Recognitions & Rankings of Meyonex Pharmaceuticals

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-MH-17-0012359

Contact details

Meyonex Pharmaceuticals Limited's registered office is in Palghar, Maharashtra. Its website is aveo.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    aveo.in
  • Registered Address
    Plot No C – 13 MIDC Tarapur Palghar, Maharashtra, India – 401506
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Meyonex Pharmaceuticals Limited, buy the company report.

Comprehensive company report
Meyonex Pharmaceuticals Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Meyonex Pharmaceuticals operates one associated brand: Aveo Pharmaceutical. Each brand links to its own profile.

BrandDescriptionWebsite
Aveo Pharmaceutical
Drug manufacturing and marketing services are provided by Aveo Pharmaceutical.aveo.in

Business activity

The main business activities of Meyonex Pharmaceuticals are trade and manufacturing. In detail, this covers wholesale trading and chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Meyonex Pharmaceuticals Limited, buy the company report.

Financials of Meyonex Pharmaceuticals Limited

FY 2024 filings available

Meyonex Pharmaceuticals Limited reported revenue of ₹108.15 Cr (down 19% YoY) for FY 2025.

Revenue · FY 2025
₹108.15 Cr ▼ 19%
Net profit · FY 2025
₹3.62 Cr margin 3.3%
EBITDA · FY 2025
₹10.86 Cr margin 10%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 19%
3 years · compounded
▲ 26%
5 years · compounded
▲ 37%
EBITDA CAGR growth
1 year
▼ 37%
3 years · compounded
▲ 66%
5 years · compounded
▲ 64%

Revenue fell 19% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 37%. EBITDA fell 37% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹10.86 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹3.62 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin10%
Net Profit Margin3.3%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Meyonex Pharmaceuticals Limited, buy the company report.

Board of directors of Meyonex Pharmaceuticals Limited

Meyonex Pharmaceuticals has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Arvind Awadhnath Sharma
Also directs: Aveo India Healthcare Private Limited, Westfin International Private Limited
Director17 Jan 201511 Years 9 MonthsCurrent
Vinod Kumar Sharma
Also directs: Aveo India Healthcare Private Limited, Westfin International Private Limited, Appearance Infrastructure Private Limited and 2 more
Director28 Mar 20188 Years 7 MonthsCurrent
Shivani SharmaAdditional Director04 Oct 20242 Years 0 MonthsCurrent
View all directors

Peer comparison

Meyonex Pharmaceuticals Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Viplus Pharmaceuticals Private Limited₹109.48 Cr (FY 2024)83.0%Hyderabad, Telangana, India
Novus Life Sciences Private Limited₹109.09 Cr (FY 2025)96.0%Mumbi, Maharashtra, India
Meyonex Pharmaceuticals Limitedthis company₹108.15 Cr (FY 2025)₹3.62 Cr3.3%-19.0%48Palghar, Maharashtra, India
Unimed Technologies Limited.₹107.74 Cr (FY 2025)11.0%Vadodara, Gujarat, India
Power Pharmaceuticals Private Limited₹107.38 Cr (FY 2025)6.0%Chennai, Tamil Nadu, India

To see the full peer comparison of Meyonex Pharmaceuticals Limited, buy the company report.

Auditor

Meyonex Pharmaceuticals Limited is audited by ATUL JAISWAL & ASSOCIATES for the financial year 2024.

Auditor firmFinancial yearFirm registration number
ATUL JAISWAL & ASSOCIATESFY 2024145892W

Shareholding

The shareholding of Meyonex Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Meyonex Pharmaceuticals Limited, buy the company report.

Charges & borrowings

Open charges
₹21.02 Cr
Satisfied charges
₹25 Lakh
Breakdown by lending institutions
Others₹21.02 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
28 Oct 2023100805126Others₹2.41 CrOpen
26 Sep 2023100815040Others₹11 CrOpen
26 Sep 2023100815031Others₹6.11 CrOpen
08 Feb 2023100688512Others₹1.5 CrOpen
20 Apr 2021100445895Hdfc Bank Limited₹25 LakhSatisfied

To see the full charge records of Meyonex Pharmaceuticals Limited, buy the company report.

Total charge records: 5 View all charges

Deals & funding

Meyonex Pharmaceuticals Limited has 4 deals on record (2 rights issues, 1 convertible or debt financing, 1 secondary share transfer), with disclosed funding of ₹1.24 Cr; the latest was in August 2021.

Total deals
4
Rights issues
2
Convertible or debt financing
1
Secondary share transfer
1
Disclosed funding
₹1.24 Cr

Deals on record (3 of 4)

WhenDealAmountParties
Aug 2021Secondary share transferUndisclosedBuyer: an individual
Seller: an individual
May 2020Rights issue₹1 CrInvestors: an individual
Jun 2019Rights issue₹1 CrInvestors: an individual

To see the full deal history of Meyonex Pharmaceuticals Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Meyonex Pharmaceuticals Limited has 3 MSME Form 1 returns on record between 2021 and 2022, listing 21 overdue payments to 12 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 12)

SupplierAmount dueDue sinceReported on
Skai Air Control Private Limited
G. K. Engineering
Uday Multiprint
Medpack Industries
an individual supplier

To see the full MSME payment records of Meyonex Pharmaceuticals Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Meyonex Pharmaceuticals has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
1
Associated companies
Key subsidiaries
Company NameCINShares held
Aveo India Healthcare Private LimitedU46497MH2024PTC420637

To see the full group structure of Meyonex Pharmaceuticals Limited, buy the company report.

Employees & EPFO

Meyonex Pharmaceuticals Limited has a workforce of 48 employees on its EPFO records as of Jul 31, 2025, across 1 active EPFO establishment.

Employee count
48
Active EPFO establishments
1
Employee growth
92%

GST

Meyonex Pharmaceuticals has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AANCA2009B1Z6MaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Meyonex Pharmaceuticals Limited, buy the company report.

Recent activity

Meyonex Pharmaceuticals Limited has 6 board changes on record since 2015: 3 appointments and 3 cessations. The latest: Bijoy Deb ceased to be Director on 06 Oct 2025.

Ceased
Bijoy Deb ceased to be Director.
Ceased
Varun Sharma ceased to be Director.
Charges
A charge with Others of Rs. 11.00 Cr registered on 26 Sep 2023 with Charge ID 100815040 was modified on 31 Jan 2025.
Appointed
Shivani Sharma was appointed as Additional Director.
AGM
Meyonex Pharmaceuticals Limited last Annual general meeting of members was held on 28 Sep 2024 as per latest MCA records.
Charges
A charge with Others of Rs. 6.11 Cr registered on 26 Sep 2023 with Charge ID 100815031 was modified on 29 May 2024.
Filing
Meyonex Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Charges
A charge registered on 20 Apr 2021 via Charge ID 100445895 with Hdfc Bank Limited was fully satisfied on 31 Mar 2024.
Charges
A charge with Others amounted to Rs. 2.41 Cr with Charge ID 100805126 was registered on 28 Oct 2023.
Charges
A charge with Others amounted to Rs. 6.11 Cr with Charge ID 100815031 was registered on 26 Sep 2023.
Charges
A charge with Others amounted to Rs. 11.00 Cr with Charge ID 100815040 was registered on 26 Sep 2023.
Charges
A charge with Hdfc Bank Limited of Rs. 0.25 Cr registered on 20 Apr 2021 with Charge ID 100445895 was modified on 25 Jul 2023.

6 earlier events are in the company report.

News

Frequently asked questions

Meyonex Pharmaceuticals is an active public limited company based in Palghar, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 January 2015 (11+ years old) and is registered under CIN U74120MH2015PLC261024.

Meyonex Pharmaceuticals has 3 current directors:

The latest financial statements of Meyonex Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 28 September 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Meyonex Pharmaceuticals is 27AANCA2009B1Z6, registered in Maharashtra.

The CIN (Corporate Identification Number) of Meyonex Pharmaceuticals is U74120MH2015PLC261024. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Meyonex Pharmaceuticals has 12 court cases on record: 9 filed by the company and 3 filed against it. 7 are pending. Most are in the high courts.

Meyonex Pharmaceuticals was incorporated on 17 January 2015, making it 11+ years old. It is registered with the Registrar of Companies, Mumbai.

Meyonex Pharmaceuticals has 4 deals on record (2 rights issues, 1 convertible or debt financing, 1 secondary share transfer), with disclosed funding of ₹1.24 Cr; the latest was in August 2021.

The peers of Meyonex Pharmaceuticals by revenue are Viplus Pharmaceuticals Private Limited, Novus Life Sciences Private Limited, Unimed Technologies Limited, Power Pharmaceuticals Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).

Bijoy Deb ceased to be Director on 06 Oct 2025. Varun Sharma ceased to be Director on 08 Mar 2025. Shivani Sharma was appointed as Additional Director on 04 Oct 2024. Meyonex Pharmaceuticals has 6 board changes on record in total.

Yes, Meyonex Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-17-0012359).

Meyonex Pharmaceuticals has 3 MSME Form 1 returns on record between 2021 and 2022, listing 21 overdue payments to 12 micro and small suppliers. The latest return was filed on 30 Apr 2022.